3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
4
INDUSTRY
1
FED
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Uterine Prolapse
1
Uterine Cervical Neoplasms
1
Precancerous Conditions
1
Ovarian Neoplasms
1
Menstruation Disturbances
1
Leiomyoma
1
Endometriosis
1
Endometrial Neoplasms
1
Adenomyosis
1
Interventions
telapristone acetate
18
vilaprisan
12
relugolix
11
estradiol, norethindrone drug combination
9
asoprisnil
9
Estradiol
8
elagolix
7
Uterine Myomectomy
7
ulipristal acetate
6
Norethindrone Acetate
6
Leuprolide
5
linzagolix
4
Uterine Artery Embolization
3
Sugars
3
ulipristal
2
Progestins
2
Mifepristone
2
epigallocatechin gallate
1
carbetocin
1
Vitamin D
1
Vitamin B 6
1
Therapeutics
1
Standard of Care
1
Sodium Chloride
1
Robotic Surgical Procedures
1
Radiofrequency Ablation
1
Progesterone
1
Microbial Collagenase
1
Megestrol Acetate
1
Medroxyprogesterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leiomyoma
×
Hysterectomy
×
Clear all
NCT07120945
2026-06-02
Embrace Gyn
Medtronic - MITG
Phase NA
Active not recruiting
70 enrolled